Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial

L. Davidescu (Oradea, Romania), P. Chanez (Marseille, France), G. Ursol (Kropyvnytskyi, Ukraine), O. Korzh (Kharkiv, Ukraine), V. Deshmukh (Nagpur, India), L. Kuryk (Kiev, Ukraine), N. Monja-Marie (Brandfort, South Africa), O. Godlevska (Kharkiv, Ukraine), G. Devouassoux (Lyon, France), E. Khodosh (Kharkiv, Ukraine), E. Israel (Boston, United States of America), C. Mansfield (Paris, France), O. Hermine (Paris, France)

Source: Virtual Congress 2020 – ALERT: Asthma in adults and children
Session: ALERT: Asthma in adults and children
Session type: Clinical trials session
Number: 4612

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Davidescu (Oradea, Romania), P. Chanez (Marseille, France), G. Ursol (Kropyvnytskyi, Ukraine), O. Korzh (Kharkiv, Ukraine), V. Deshmukh (Nagpur, India), L. Kuryk (Kiev, Ukraine), N. Monja-Marie (Brandfort, South Africa), O. Godlevska (Kharkiv, Ukraine), G. Devouassoux (Lyon, France), E. Khodosh (Kharkiv, Ukraine), E. Israel (Boston, United States of America), C. Mansfield (Paris, France), O. Hermine (Paris, France). Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial. 4612

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: